Cargando…
Acromegaly and thyroid cancer: analysis of evolution in a series of patients
BACKGROUND: Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672811/ https://www.ncbi.nlm.nih.gov/pubmed/33292786 http://dx.doi.org/10.1186/s40842-020-00113-4 |
_version_ | 1783611209859203072 |
---|---|
author | Danilowicz, Karina Sosa, Soledad Gonzalez Pernas, Mariana Soledad Bamberger, Elizabeth Diez, Sabrina Mara Fainstein-Day, Patricia Furioso, Alejandra Glerean, Mariela Guitelman, Mirtha Katz, Débora Lemaitre, Nicole Lowenstein, Alicia del Valle Luna, Mariela Martínez, María Paz Miragaya, Karina Moncet, Daniel Ortuño, María Victoria Pignatta, Analía Ramacciotti, Constanza Fernanda Reyes, Adriana Rogozinski, Amelia Susana Slavinsky, Patricia Tkatch, Julieta Pitoia, Fabián |
author_facet | Danilowicz, Karina Sosa, Soledad Gonzalez Pernas, Mariana Soledad Bamberger, Elizabeth Diez, Sabrina Mara Fainstein-Day, Patricia Furioso, Alejandra Glerean, Mariela Guitelman, Mirtha Katz, Débora Lemaitre, Nicole Lowenstein, Alicia del Valle Luna, Mariela Martínez, María Paz Miragaya, Karina Moncet, Daniel Ortuño, María Victoria Pignatta, Analía Ramacciotti, Constanza Fernanda Reyes, Adriana Rogozinski, Amelia Susana Slavinsky, Patricia Tkatch, Julieta Pitoia, Fabián |
author_sort | Danilowicz, Karina |
collection | PubMed |
description | BACKGROUND: Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution. METHODS: This is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0. RESULTS: Median age of patients at diagnosis of acromegaly was 49.5 years (range 12–69). The median delay in diagnosis of acromegaly was 3 years (range 0.5–23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5 years (18–69). At the moment of diagnosis of DTC, 58.3% of the patients had active acromegaly. Median time from DTC diagnosis to acromegaly control was 1.25 years (0.5–7). Mean DTC tumor diameter of the biggest lesion was 14.6 ± 9.2 mm, being multifocal in 37.5%. All tumors were papillary carcinomas, two cases being of an aggressive variety. Lymph node dissection was performed in 8 out of 24 patients and 62.5% had metastases. Only one patient had distant metastases. Radioiodine ablation was given to 87.5% of patients. Nineteen patients (79%) were stage I, four (17%) stage II and one (4%) stage IVb. Initial RR was low in 87% (21/24), intermediate in 9% (2/24) and high in 4% (1/24) patient. RFU was: 83% (19/23) patients with no evidence of disease, 9% (2/23) with indeterminate response, 4% (1/23) with biochemical incomplete response and 4% (1/23) with structural incomplete response, at a median time of FU of 36.5 months. When comparing RFU between acromegalics and controls no statistically significant differences were found. CONCLUSIONS: Patients with acromegaly and DTC mostly had a low initial RR. When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40842-020-00113-4. |
format | Online Article Text |
id | pubmed-7672811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76728112020-11-19 Acromegaly and thyroid cancer: analysis of evolution in a series of patients Danilowicz, Karina Sosa, Soledad Gonzalez Pernas, Mariana Soledad Bamberger, Elizabeth Diez, Sabrina Mara Fainstein-Day, Patricia Furioso, Alejandra Glerean, Mariela Guitelman, Mirtha Katz, Débora Lemaitre, Nicole Lowenstein, Alicia del Valle Luna, Mariela Martínez, María Paz Miragaya, Karina Moncet, Daniel Ortuño, María Victoria Pignatta, Analía Ramacciotti, Constanza Fernanda Reyes, Adriana Rogozinski, Amelia Susana Slavinsky, Patricia Tkatch, Julieta Pitoia, Fabián Clin Diabetes Endocrinol Research Article BACKGROUND: Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution. METHODS: This is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0. RESULTS: Median age of patients at diagnosis of acromegaly was 49.5 years (range 12–69). The median delay in diagnosis of acromegaly was 3 years (range 0.5–23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5 years (18–69). At the moment of diagnosis of DTC, 58.3% of the patients had active acromegaly. Median time from DTC diagnosis to acromegaly control was 1.25 years (0.5–7). Mean DTC tumor diameter of the biggest lesion was 14.6 ± 9.2 mm, being multifocal in 37.5%. All tumors were papillary carcinomas, two cases being of an aggressive variety. Lymph node dissection was performed in 8 out of 24 patients and 62.5% had metastases. Only one patient had distant metastases. Radioiodine ablation was given to 87.5% of patients. Nineteen patients (79%) were stage I, four (17%) stage II and one (4%) stage IVb. Initial RR was low in 87% (21/24), intermediate in 9% (2/24) and high in 4% (1/24) patient. RFU was: 83% (19/23) patients with no evidence of disease, 9% (2/23) with indeterminate response, 4% (1/23) with biochemical incomplete response and 4% (1/23) with structural incomplete response, at a median time of FU of 36.5 months. When comparing RFU between acromegalics and controls no statistically significant differences were found. CONCLUSIONS: Patients with acromegaly and DTC mostly had a low initial RR. When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40842-020-00113-4. BioMed Central 2020-11-17 /pmc/articles/PMC7672811/ /pubmed/33292786 http://dx.doi.org/10.1186/s40842-020-00113-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Danilowicz, Karina Sosa, Soledad Gonzalez Pernas, Mariana Soledad Bamberger, Elizabeth Diez, Sabrina Mara Fainstein-Day, Patricia Furioso, Alejandra Glerean, Mariela Guitelman, Mirtha Katz, Débora Lemaitre, Nicole Lowenstein, Alicia del Valle Luna, Mariela Martínez, María Paz Miragaya, Karina Moncet, Daniel Ortuño, María Victoria Pignatta, Analía Ramacciotti, Constanza Fernanda Reyes, Adriana Rogozinski, Amelia Susana Slavinsky, Patricia Tkatch, Julieta Pitoia, Fabián Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title | Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title_full | Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title_fullStr | Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title_full_unstemmed | Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title_short | Acromegaly and thyroid cancer: analysis of evolution in a series of patients |
title_sort | acromegaly and thyroid cancer: analysis of evolution in a series of patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672811/ https://www.ncbi.nlm.nih.gov/pubmed/33292786 http://dx.doi.org/10.1186/s40842-020-00113-4 |
work_keys_str_mv | AT danilowiczkarina acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT sosasoledad acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT gonzalezpernasmarianasoledad acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT bambergerelizabeth acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT diezsabrinamara acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT fainsteindaypatricia acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT furiosoalejandra acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT glereanmariela acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT guitelmanmirtha acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT katzdebora acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT lemaitrenicole acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT lowensteinalicia acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT delvallelunamariela acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT martinezmariapaz acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT miragayakarina acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT moncetdaniel acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT ortunomariavictoria acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT pignattaanalia acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT ramacciotticonstanzafernanda acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT reyesadriana acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT rogozinskiameliasusana acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT slavinskypatricia acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT tkatchjulieta acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients AT pitoiafabian acromegalyandthyroidcanceranalysisofevolutioninaseriesofpatients |